Kyverna Initiates BLA Submission for Miv-cel in SPS, Reports Improved Q1 Financials and Strong Clinical Progress

summarizeSummary

Kyverna Therapeutics initiated a BLA submission for miv-cel in SPS, reported improved Q1 financials with a 12-month cash runway, and highlighted strong clinical progress for its lead programs.

check_boxKey Events

• BLA Submission Initiated for Miv-cel in SPS

  Kyverna initiated a rolling Biologics License Application (BLA) submission for miv-cel in Stiff Person Syndrome (SPS) in May 2026, seeking priority review under its RMAT designation. This follows positive Phase 2 clinical trial results presented in April 2026.

• Improved Q1 Financial Performance

  The company reported a net loss of $(39.7) million for the three months ended March 31, 2026, an improvement from a net loss of $(44.6) million in the same period last year. Net cash used in operating activities also decreased to $(41.6) million from $(44.9) million year-over-year.

• Adequate Cash Runway

  As of March 31, 2026, Kyverna had $236.4 million in cash, cash equivalents, and marketable securities, which management estimates will fund operations for at least the next 12 months.

• Positive Longer-Term gMG Data and Phase 3 Enrollment

  Positive longer-term follow-up data from the Phase 2 KYSA-6 trial of miv-cel in generalized myasthenia gravis (gMG) were presented in April 2026, showing durable clinical responses. Phase 3 registrational trial enrollment is ongoing.

auto_awesomeAnalysis

Kyverna Therapeutics has initiated a rolling Biologics License Application (BLA) submission for its lead product candidate, miv-cel, in Stiff Person Syndrome (SPS), seeking priority review under its Regenerative Medicine Advanced Therapy (RMAT) designation. This marks a critical step towards potential market approval and commercialization for a therapy addressing a rare and debilitating autoimmune disease. The company also reported an improved net loss of $(39.7) million for Q1 2026, compared to $(44.6) million in Q1 2025, and a reduced cash burn from operations. With $236.4 million in cash and marketable securities, management projects a cash runway of at least 12 months, alleviating near-term liquidity concerns. Additionally, the company announced the appointment of a new Chief Technology Officer, Mayo Pujols, and continues to advance other miv-cel programs with positive longer-term Phase 2 data in generalized myasthenia gravis (gMG) and an accepted IND for KYV-102.